In the Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer, the prespecified ...
Compass Therapeutics (CMPX) is back on investors’ radar after fresh analysis of the biliary tract cancer market highlighted its lead candidate CTX-009 as a key emerging therapy in this growing ...
4d
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing
This clinical-stage biotech develops antibody therapeutics targeting cancer, with a pipeline focused on oncology and ...
CTX-009 demonstrated a 42% overall response rate (ORR) based on 10 patients with Partial Responses (PRs), including 9 PRs confirmed by RECIST 1.1 and 1 PR pending confirmation CTX-009 demonstrated ...
The first patient was dosed in the Phase 1 dose escalation trial of CTX-8371.This study is conducted in patients with advanced solid tumors who progressed on at least one prior regimen containing a ...
BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based ...
The expression of CD137 on immune cells has made the protein receptor an attractive target in the development of new cancer immunotherapy drugs. Now, Compass Therapeutics has some early data showing ...
The Compass Therapeutics IPO is set to hit the market. The company saw successful preclinical trials and hopes to have its products approved by 2022. Now investors are interested in Compass ...
Compass Therapeutics, Inc. (NASDAQ:CMPX) announced statistically significant topline data on Tuesday on the primary efficacy endpoint for COMPANION-002, the company’s ongoing Phase 2/3 trial of ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Compass Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary antibody therapeutics intended to engage the immune system to treat both ...
Initial programs to focus on immuno-oncology, inflammation and autoimmune disorders Compass Therapeutics, a biotechnology company committed to the ambitious goal of comprehensively drugging the human ...
BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results